Compare BEDU & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEDU | ANVS |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 53.3M |
| IPO Year | 2017 | 2020 |
| Metric | BEDU | ANVS |
|---|---|---|
| Price | $2.19 | $4.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 5.5K | ★ 4.0M |
| Earning Date | 01-23-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,321,752.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $1.11 |
| 52 Week High | $2.28 | $6.37 |
| Indicator | BEDU | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 64.94 |
| Support Level | $2.18 | $4.12 |
| Resistance Level | $2.20 | $4.82 |
| Average True Range (ATR) | 0.03 | 0.54 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 35.71 | 53.78 |
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.